ArriVent BioPharma/$AVBP
1D1W1MYTD1Y5YMAX
Capital at risk
About ArriVent BioPharma
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
- Ticker
- $AVBP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Newtown Square, United States
- Website
- arrivent.com
AVBP Metrics
BasicAdvanced
$1.4B
-
-$3.70
1.37
-
Price and volume
Market cap
$1.4B
Beta
1.37
52-week high
$35.83
52-week low
$17.00
Average daily volume
554K
Financial strength
Current ratio
14.156
Quick ratio
13.4
Long term debt to equity
0
Total debt to equity
0.001
Profitability
Management effectiveness
Return on assets (TTM)
-33.11%
Return on equity (TTM)
-53.25%
Valuation
Price to book
3.86
Price to tangible book (TTM)
3.86
Price to free cash flow (TTM)
-8.796
Free cash flow yield (TTM)
-11.37%
Free cash flow per share (TTM)
-3.331
Growth
Earnings per share change (TTM)
-7.93%
3-year earnings per share growth (CAGR)
-54.16%
What the Analysts think about AVBP
Analyst ratings (Buy, Hold, Sell) for ArriVent BioPharma stock.
Analyst projections of the future price of ArriVent BioPharma stock.
Bulls say / Bears say
FURVENT Phase 3 topline data for first-line EGFR exon 20 insertion NSCLC is expected in the second half of 2026, providing a potentially significant near-term catalyst for firmonertinib. (ArriVent BioPharma)
ArriVent had $373.1 million in cash and investments as of June 30, 2026, which management expects to fund operations into 2028. This reduces the immediate need for another financing before important clinical readouts. (ArriVent BioPharma)
The pipeline is broadening beyond firmonertinib: ARR-217 advanced into Phase 1b dose optimization, while ARR-002 received FDA IND clearance and was licensed to Allist in Greater China with potential payments of up to $80.6 million plus royalties. (ArriVent BioPharma) (SEC)
FURVENT Phase 3 topline data moved from a mid-2026 projection in May to the second half of 2026 in August, highlighting timing uncertainty around the key value-driving catalyst. (ArriVent BioPharma) (ArriVent BioPharma)
ArriVent remains pre-revenue and loss-making: it reported a $93.2 million net loss and $81.5 million of operating cash burn for the six months ended June 30, 2026. The company expects additional losses until commercialization, leaving valuation highly dependent on successful clinical and regulatory execution. (SEC)
Although the June financing strengthened liquidity, ArriVent sold 5.36 million shares for $140.0 million in the first half of 2026 and retained capacity for approximately $229.1 million of additional ATM issuance, creating ongoing dilution risk. Firmonertinib and ARR-217 also carry substantial milestone and royalty obligations to licensing partners. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
AVBP Financial Performance
Revenues and expenses
AVBP Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing AVBP
AllUSDGBPEUR
Fund name | Fund size | $AVBP weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.09% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.09% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.